亚砷酸联合EPOCH方案治疗复发难治性非霍奇金淋巴瘤临床分析

Clinical study on arsenic trioxide combined with EPOCH regimen in the treatment of relapse and refractory non-Hodgkin's lymphoma

目的观察亚砷酸(ATO)联合EPOCH方案治疗复发难治性非霍奇金淋巴瘤(NHL)的疗效和不良反应。方法收集我科2010年7月至2015年6月收治的16例经病理确诊的NHL患者,均为复发难治性,采用亚砷酸联合EPOCH方案化疗。结果 16例中CR 5例,PR 6例,SD 3例,PD 2例。全组患者中位生存期13个月。主要不良反应为胃肠道反应、骨髓抑制、脱发。结论亚砷酸联合EPOCH方案治疗复发难治性NHL疗效较好,不良反应可控,值得基层医院推广。

Objective To observe the effect and toxicity of arsenic trioxide(ATO) combined with EPOCH regimen for patients with relapse and refractory non-Hodgkin's lymphoma(NHL). Methods A total of 16 patients with pathologically diagnosed NHL from July 2010 to June 2015 were recurrent or refractory. They were treated by ATO combined with EPOCH regimen. Results Among the 16 cases, there are 5 cases of complete response(CR) and 6 cases of partial response(PR), 3 cases of stable disease(SD) and 2 cases of progressive disease(PD). The median survival time was 13 months. Main side effects were gastrointestinal reactions, myelosuppression, and lipsotrichia. Conclusion ATO combined with EPOCH regimen is effective for patients with recurrent and refractory NHL and has manageable toxicities, which is worthy of promotion in primary hospitals.